** Drug developer Summit Therapeutics' SMMT.O shares rise 4.9% to $21.23 premarket
** Citigroup upgrades to "buy" from "neutral" citing strong confidence in HARMONi-2 trial for cancer drug ivonescimab, with chance of favorable results by end of 2025
** Last month, co announced a collaboration with Pfizer PFE.N to study ivonescimab in combination with Pfizer's antibody drug conjugates (ADCs) across various tumor types
** Brokerage says trial success could make ivonescimab a groundbreaking therapy in NSCLC (non-small cell lung cancer)
** $35 PT for Summit represents ~53% upside to last close
** Analysts' average rating is equivalent of "buy"; median PT $44 - data compiled by LSEG
** Shares rose 13.4% YTD vs 12.5% increase in S&P 500 biotechnology index .SPLRCTKBI
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。